medigraphic.com

2020, Number 1

<< Back Next >>

Rev Cuba Endoc 2020; 31 (1)

Usefulness of the tolerance test of mixed food with Nutrial I for the assessment of beta cells function in diabetes type 1

Cabrera RE, Torres LY, Cubas DI, Rodríguez AJ, Vázquez IBM, Ruíz RM, García GY, Prieto NC, Echevarría VR, Álvarez ÁA, Domínguez AE, Conesa AI, González CT, Robles TE, Turcios TS, Hernández CP

Language: Spanish
References: 40
Page:
PDF size: 477.19 Kb.


ABSTRACT

Introduction: The tolerance test of mixed food is considered the gold standard for the measurement of endogenous insulin production in patients with diabetes type 1.
Objective: To determine the usefulness of the tolerance test of mixed food with Nutrial I to assess the β-cells function in patients with diabetes type 1 of recent diagnosis and the relation of this function with some clinical and biochemical characteristics.
Methods: There were studied biochemical variables as the blood glucose, glycosylated haemoglobin (HbA1c), C-peptide and lipid fractions. The tolerance test of mixed food with Nutrial I was applied to 18 individuals with diabetes type 1 of recent diagnosis and in 8 volunteers aged between 19 and 35 years old. The consumption of Nutrial I supplement was calculated according to the weight of the patient. Samples were obtained for blood glucose and C-peptide at -10, 0, 30, 60, 90 and 120 minutes.
Results: There were observed high concentrations of glycemia and decreased amounts of C-peptide during the tolerance test of mixed food in recently diagnosed type 1 diabetics in comparison with the volunteers, as well as differences in areas under the curve of C-peptide (AUC-pc) (p= 0.001). In the recently diagnosed type 1 diabetics was evident a negative correlation between the AUC-pc with fasting plasma glucose levels (r= -0,747; p(0.0001) and HbA1c (r= -0,535; p= 0.022). On the contrary, it was found a positive correlation between the AUC-pc and fasting C-peptide (r = 0.722; p = 0.001). The AUC-pc after the tolerance test of mixed food was greater in subjects with fasting blood glucose < 7 mmol/L with respect to the subjects with fasting blood glucose ( 7 mmol/L (p= 0.012).
Conclusions: The use of Nutrial I in the tolerance test of mixed food was useful in the assessment of the role of the β-cells in patients with recently diagnosed diabetes type 1. Low values of fasting blood glucose during this test are indirect markers of a residual function of (cells more preserved in type 1 diabetics of recent diagnosis.


REFERENCES

  1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82.

  2. Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2018;7:R38-R46.

  3. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, Atkinson MA. Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes. 2016;65:719-31.

  4. Ling Q, Lu J, Li J, Xu Q, Zhu D, Bi Y. Risk of beta-cell autoimmunity presence for progression to type 1 diabetes: A systematic review and meta-analysis. J Autoimm. 2018;86:9-18.

  5. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl. 1):S14–S31.

  6. Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metabolism. 2020;31:46-61.

  7. Karras SN, Koufakis T, Zebekakis P, Kotsa K. Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun. World J Diabetes. 2019;10(4):234-40.

  8. Pathak V, Pathak NM, O'Neill CL, Guduric-Fucns J, Medina RJ. Therapies for type 1 diabetes: Current scenario and future perspective. Clin Med Insights Endocrinol Diabetes Internet] 2019 [citado: 15/09/2019];12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501476/pdf/10.1177_1179551419844521.pdf

  9. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G et al. Residual insulin production and pancreatic -cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-53.

  10. Regnell SE, Lernmark A. Early prediction of autoimmune (type 1) diabetes. Diabetologia. 2017;60:1370-81.

  11. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31:1966-71.

  12. Besser REJ, Shields BM, Casas R, Hatterley AT, Ludvigsson J. Lessons from the Mixed-Meal Tolerance Test: Use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care. 2013;36:195–201.

  13. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, et al. Insulin secretion in type 1 diabetes. Diabetes. 2004;53:426-33.

  14. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, et al. Glucose and C peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2008;31:2188-92.

  15. Nordwall M, Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev. 2008;24:472-79.

  16. Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes. 2014;63:739-48.

  17. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012;35:465-70.

  18. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38:476-81.

  19. DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, et al. Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatr Diabetes. 2016;17:237-43.

  20. Ehlers MR. Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes. J Investig Med. 2016;64:7–13.

  21. Van Buecken DE, Greenbaum CJ. Residual C-peptide in type 1 diabetes: what do we really know? Pediatr Diabetes. 2014;15:84-90.

  22. Ruan Y, Willemsen RH, Wilinska ME, Tauschmann M, Dunger DB, Hovorka R. Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area under-curve of plasma C-peptide concentration. Pediatr Diabetes. 2019;20:282-85.

  23. Boyle KD, Keyes-Elstein L, Ehler MR, McNamara J, Rigby MR, Gitelman SE, et al. Two- and four-hour tests differ in capture of C-peptide responses to a mixed meal in type 1 diabetes. Diabetes Care. 2016;39:e76-8.

  24. Ludvigsson J. C-peptide in diabetes diagnosis and therapy. Front Biosc Elit. 2013;5:214-23.

  25. Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeu KJ, Hao W, et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest. [Internet] 2020 [citado: 15/11/2019]. Disponible en: https://www.jci.org/articles/view/134057/pdf

  26. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry. WHO. Technical Report Series 854 Geneva, Switzerland. 1995.

  27. Unger G, Benozzi SF, Fernando Perruzza F, Pennacchiotti GL. Índice triglicéridos y glucosa: un indicador útil de insulino resistencia. Endocrinol Nutr. 2014;61:533-40.

  28. Greenbaum CJ, Buckingham B, Chase HP, Krisher J. Metabolic tests to determine risk for type 1 diabetes in clinical trials. Diabetes Metab Res Rev. 2011;27:584-89.

  29. The DCCT Research Group: Effect of intensive therapy on residual β-cell function in patients with type I diabetes in the Diabetes Control and Complications Trial. Ann Intern Med. 1998;128:517-23.

  30. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-64.

  31. Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev. 2014; 30:154-62.

  32. Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multicentre study. Diabet. Med. 2014;31:399-402.

  33. Dejgaard TF, Frandsen C, Kielgast U, Andersen HU, Thorsteinsson B, Krarup T, et al. Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: The New-Lira Trial. Diabetes [Internet] 2019 [citado: 15/11/2019];68 (Suppl 1). Disponible en: https://diabetes.diabetesjournals.org/content/68/Supplement_1/59-OR

  34. Hagopian W, Ferry RJ, Jr. Sherry N, Carlin D, Bonvini E, Johnson S, et al. Teplizumab preserves C-peptide in recent onset type 1 diabetes: two-year results from the randomized, placebo controlled. Protégé trial. Diabetes. 2013;62:3901-08.

  35. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, et al. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell function and improves HbA1c in new-onset type 1 diabetes. Diabetes Care. 2018;41:1917-25.

  36. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, et al. Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-Cell ratios in new-onset type 1 diabetes: Two-year clinical trial data. Diabetes. 2019;68:1267-76.

  37. Berger B, Stenstro G, Sundkvist G: Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest. 2000;60:687-94.

  38. Buchanan K, Mehdi AM, Hughes I, Cotterill A, Le Cao KA, Thomas R, et al. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes. Pediatr Diabetes. 2019;20:166-71.

  39. Hernández M, Mollo A, Marsal JR, Esquerda A, Capel I, Puig Domingo M, et al. and on behalf of the Action LADA consortium. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr Disord [Internet] 2015 [citado: 15/11/2019];15:1. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297398/pdf/12902_2014_Article_301.pdf

  40. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30:803-17.




2020     |     www.medigraphic.com